Physician profile
Bree M Pell
NPI 1598035974
$2,401.68
in general payments reported to CMS, 2019-2025
21 companies · $304 in 2025
The $304 reported for 2025 was more than what a typical Family provider received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $420 · 2022: $616 · 2023: $744 · 2024: $318 · 2025: $304.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,266 · Education: $99.99.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,266.27 |
| Education | $99.99 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Antares Pharma, INC. | $453.81 | 2021-2025 | Xyosted, Tlando, Nocdurna |
| Astellas Pharma US INC | $372.79 | 2021-2024 | Xtandi, Myrbetriq |
| Axonics, INC. | $220.04 | 2021-2023 | Axonics, Bulkamid |
| Sumitomo Pharma America, INC. | $219.55 | 2023-2025 | Gemtesa |
| Janssen Biotech, INC. | $202.30 | 2023-2025 | Erleada |
| Endo Pharmaceuticals INC. | $199.48 | 2021-2023 | Xiaflex, Aveed |
| Endo USA, INC. | $151.55 | 2024-2025 | Xiaflex, Aveed |
| Abbvie INC. | $122.56 | 2021-2025 | |
| 180 Medical, INC. | $102.27 | 2023-2025 | Cure Catheter |
| C. R. Bard, INC. & Subsidiaries | $42.85 | 2025 | Magic3 Go Intermittent Urinary Catheter |
| Ferring Pharmaceuticals INC. | $42.21 | 2024-2025 | Adstiladrin |
| Rochester Medical Corporation | $41.31 | 2021 | |
| Bayer Healthcare Pharmaceuticals INC. | $34.67 | 2021 | |
| Accord Healthcare, INC. | $32.40 | 2023 | |
| Boston Scientific Corporation | $30.40 | 2023 | Rezum Generator |
Show all 21 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Halozyme INC | $30.07 | 2023 | |
| Myriad Genetic Laboratories, INC. | $24.30 | 2023 | Prolaris |
| Sun Pharmaceutical Industries INC. | $21.34 | 2022 | |
| Tolmar, INC. | $20.67 | 2023 | |
| Urovant Sciences INC | $20.07 | 2022 | |
| Merck Sharp & Dohme LLC | $17.04 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Bree Pell listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.